9th Translational Research Conference
Myelodysplastic Syndromes
April 12-14, 2024 - Budapest, Hungary
Chairpersons: Pierre Fenaux, Katharina Götze, Mikkael Sekeres

Friday, April 12th, 2024

08:30–08:40 Welcome

SESSION I – The sinister origins of myelodysplastic syndromes
Chair: Katharina Götze (Munich)

08:40-08:45	Introduction	Katharina Götze (Munich)
08:45-09:00	Clonal haematopoiesis	Katharina Götze (Munich)
09:00-09:05	*Discussion*	
09:05-09:20	Methylation machinations	Maria Figueroa (Miami)
09:20-09:25	*Discussion*	
09:25-09:40	Germline mutations	Marie Sébert (Paris)
09:40-09:45	*Discussion*	
09:45-10:00	Therapy related myelodysplastic syndromes	Jean-Baptiste Micol (Paris)
10:00-10:05	*Discussion*	
10:05-10:12	**Selected brief oral communication:** Mutational Profile and Dynamics of PPM1D-mutant Clones in the Spectrum of Myeloid Disorders	Jean Pegliasco (Villejuif)
10:12-10:15	*Discussion*	
10:15-10:45	*Panel discussion*	

10:45-11:15 Coffee Break

SESSION II – The interplay between myelodysplastic syndromes, inflammatory, and immune abnormalities
Chair: Marc Raaijmakers (Rotterdam)

11:15-11:20	Introduction	Marc Raaijmakers (Rotterdam)
11:20 -11:35	The immunome	Shahram Kordasti (London)
11:35-11:40	*Discussion*	
11:40-11:55	The niche	Marc Raaijmakers (Rotterdam)
11:55-12:00	*Discussion*	

12:00-12:15	VEXAS syndrome	*David B. Beck (New York) virtual*
12:15-12:22	**Selected brief oral communication:** Clinical efficacy of erythroid stimulating agent in VEXAS syndrome with or without myelodysplastic syndrome: a multicentric retrospective study	Maël Heiblig (Pierre Bénite)
12:22-12:25	*Discussion*	
12:25-12:55	**Roundtable I:** Immune /inflammatory disorders and myelodysplastic syndromes: Chicken and the egg, or the same cause for both? Speakers: Shahram Kordasti (London), Marc Raaijmakers (Rotterdam), Pierre Fenaux (Paris)	
12:55-14:35	***Lunch***	

SESSION III – What's in a name? Classifying myelodysplastic syndromes
Chair: Amer Zeidan (New Haven)

14:35-14:40	Introduction	Amer Zeidan (New Haven)
14:40-14:55	Diagnosing myelodysplastic syndromes: Classical tools	Aristoteles Giagounidis (Düsseldorf)
14:55-15:00	*Discussion*	
15:00-15:15	Diagnosing myelodysplastic syndromes: NGS	Klaus Metzeler (Leipzig)
15:15-15:20	*Discussion*	
15:20-15:35	WHO v. ICC	Lionel Adès (Paris)
15:35-15:40	*Discussion*	
15:40-15:47	**Selected brief oral communication:** Validation of the diagnostic potential of 17 immunophenotypic core markers defined by ELN-iMDS-Flow in an independent cohort of MDS patients	Coen Veenstra (Amsterdam)
15:47-15:50	*Discussion*	
15:50-16:20	*Panel discussion*	
16:20-16:50	***Coffee break***	

SESSION IV – New tools to explore myelodysplastic syndromes
Chair: Valeria Santini (Florence)

16:50-16:55	Introduction	Valeria Santini (Florence)
16:55-17:10	AI/ML to diagnose myelodysplastic syndromes	Carsten Marr (Munich)
17:10-17:15	*Discussion*	
17:15-17:30	AI/ML to predict myelodysplastic syndromes prognosis	Aziz Nazha (Newark)
17:30-17:35	*Discussion*	
17:35-17:50	AI/ML to predict myelodysplastic syndromes response to drugs	Jaroslaw Maciejewski (Cleveland)
17:50-17:55	*Discussion*	

17:55-18:10 Comparing prognostic schemas — Torsten Haferlach (Munich)
18:10-18:15 *Discussion*

18:15-18:22 **Selected brief oral communication:**
Final analysis of HOVON-SAKK studies to evaluate the prognostic value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes treated with intensive chemotherapy — Coen Veenstra (Amsterdam)
18:22-18:25 *Discussion*

18:25-18:55 *Panel discussion*

19:00 – 20:00 Mentored Poster Walks and Welcome Get Together stand up buffet dinner
Biology poster leaders: Maria Figueroa (Miami) & Michaela Fontenay (Paris)
Clinical poster leaders : Valeria Santini (Florence) & Amer Zeidan (New Haven)

Saturday, April 13th, 2024

09:00-10:00 3 Simultaneous Meet the Expert sessions

1, Practical management of higher risk myelodysplastic syndromes — Pierre Fenaux (Paris)
2, Practical management of anemia of lower risk myelodysplastic syndromes — Valeria Santini (Florence)
3, Practical management of chronic myelomonocytic leukaemia — Katharina Götze (Munich)

10:00-10:30 Coffee break

SESSION V – Special populations
Chair: Pierre Fenaux (Paris)

10:30-10:35 Introduction — Pierre Fenaux (Paris)

10:35-10:50 The many faces of TP53 — Claudia Haferlach (Munich)
10:50-10:55 *Discussion*

10:55-11:10 Myelodysplastic syndrome with SF3B1 gene mutation — Michaela Fontenay (Paris)
11:10-11:15 *Discussion*

11:15-11:30 A role for mature cells of the leukemic clone in chronic myelomonocytic leukemia — Dorothée Selimoglu-Buet (Paris)
11:30-11:35 *Discussion*

11:35 - 11:50 Frailty in MDS Patients — Rena Buckstein (Toronto)
11:50 – 11:55 *Discussion*

11:55-12:02 **Selected brief oral communication:**
Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukaemia: results of a multicentre study — Yu-Hung Wang (Taipei)
12:02-12:05 *Discussion*

12:05-12:35 *Panel discussion*

12:35-14:00 Lunch

SESSION VI – Treatment of lower-risk myelodysplastic syndromes
Chair: Maria Diez Campelo (Salamanca)

14:00-14:05	Introduction	Maria Diez Campelo (Salamanca)
14:05-14:20	Standards for managing anemia	Eva Hellström-Lindberg (Stockholm)
14:20-14:25	*Discussion*	
14:25-14:40	Defining and treating relapsed/refractory lower-risk myelodysplastic syndromes	Valeria Santini (Florence)
14:40-14:45	*Discussion*	
14:45-15:00	Response criteria for LR myelodysplastic syndromes	Mikkael Sekeres (Miami)
15:00-15:05	*Discussion*	
15:05-15:12	**Selected brief oral communication:** Preclinical studies demonstrating efficacy of tasquinimod in myelodysplastic neoplasms	Manja Wobus (Dresden)
15:12-15:15	*Discussion*	
15:15-15:45	*Panel discussion*	
15:45-16:15	***Coffee break***	

SESSION VII – Treatment of higher-risk myelodysplastic syndromes
Chair: Mikkael Sekeres (Miami)

16:15-16:20	Introduction	Mikkael Sekeres (Miami)
16:20-16:35	HMAs -- a party of one	Guillermo Garcia-Manero (Houston)
16:35-16:40	*Discussion*	
16:40-16:55	Hypomethylating agent combinations	Mikkael Sekeres (Miami)
16:55-17:00	*Discussion*	
17:00-17:15	Response criteria for HR myelodysplastic syndromes	Amer Zeidan (New Haven)
17:15-17:20	*Discussion*	
17:20-17:27	**Selected brief oral communication:** Next generation of hypomethylating agents with improved anti-leukemia activity	Matthias Heiss (Munich)
17:27-17:30	*Discussion*	
17:30-**18:00**	*Panel discussion*	

Sunday, April 14th, 2024

07:30-08:30	**3 Simultaneous Breakfast Meet the Expert Sessions**	
	1, How to best use NGS in practice	Torsten Haferlach (Munich)
	2, IPSS m in practice	Lionel Adès (Paris)
	3, Response criteria in myelodysplastic syndromes	Amer Zeidan (New Haven)

SESSION VIII – Transplantation
Chair: Guillermo Garcia-Manero (Houston)

08:35-08:40	Introduction	Guillermo Garcia-Manero (Houston)
08:40-09:15	Overview of allo SCT and allo in lower risk MDS	Didier Blaise (Marseille)
09:15-09:20	*Discussion*	
09:20-09:35	Allo HSCT in aged patients	Didier Blaise (Marseille)
09:35-09:40	*Discussion*	
09:40-09:47	**Selected brief oral communication:**	
	Cord Blood Transplantation for patients with MDS in Japan	Takahashi Satoshi (Tokyo)
09:47-09:50	*Discussion*	
09:50-10:20	**Roundtable II**:	
	About conditioning and donors	
	Speakers : Didier Blaise (Marseille), Guillermo Garcia-Manero (Houston)	

10:20-10:50 Coffee break

SESSION IX – Clinical trials in myelodysplastic syndromes/chronic myelomonocytic leukaemia: Cooperative groups
Chair: Lionel Adès (Paris)

10:50-10:55	Introduction	Lionel Adès (Paris)
10:55-11:10	French, Spanish	Pierre Fenaux (Paris) & Maria Diez Campelo (Salamanca)
11:10-11:15	*Discussion*	
11:15-11:30	German, EMSCO, Italian	Katharina Götze (Munich) & Valeria Santini (Florence)
11:30-11:35	*Discussion*	
11:35-11:50	US, others	Guillermo Garcia-Manero (Houston)
11:50-11:55	*Discussion*	
11:55-12:02	**Selected brief oral communication:**	
	Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia as a Bridge Therapy to Transplant. A GESMD Study	Ines Zugasti (Barcelona)
12:02-12:05	*Discussion*	
12:05-12:35	*Panel discussion*	

12:35-12:45 Closing Remarks
MEETING CLOSURE